Skip to main content

Corinne Mary Linardic

Associate Professor of Pediatrics
Pediatrics, Hematology-Oncology
Box 102382, DUMC, Durham, NC 27710
LSRC Bldg Rm B361F, Research Drive, Durham, NC 27710

Overview


Pediatric Sarcomas: Sarcomas are among the most difficult-to-treat cancers in pediatric oncology, with metastatic forms having the highest mortality. We have established genetically defined human cell-based models and genetically engineered murine models for the pediatric skeletal muscle cancer known as rhabdomyosarcoma. Using these models, we can study the causative role of certain genetic changes (e.g. chromosomal translocations and oncogenic RAS) in rhabdomyosarcoma formation and treatment resistance. Specific goals of this research program include the identification of signaling pathways corrupted in rhabdomyosarcoma, with focus on the PAX3::FOXO1 mutation and its downstream effectors and oncogenic RAS, and identification of new therapeutic targets for treatment of this childhood cancer.

Current Appointments & Affiliations


Associate Professor of Pediatrics · 2012 - Present Pediatrics, Hematology-Oncology, Pediatrics
Associate Professor of Pharmacology and Cancer Biology · 2012 - Present Pharmacology & Cancer Biology, Basic Science Departments
Associate Professor of Cell Biology · 2022 - Present Cell Biology, Basic Science Departments
Member of the Duke Cancer Institute · 1999 - Present Duke Cancer Institute, Institutes and Centers

In the News


Published April 29, 2025
Daily Takeaways From the AACR Annual Meeting 2025: Tuesday, April 29

View All News

Recent Publications


Towards directed therapy for fusion-positive rhabdomyosarcoma.

Journal Article Pharmacol Ther · December 2025 Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood. The fusion-positive variant of rhabdomyosarcoma has the dubious distinction of being one of the most difficult to cure childhood cancers. Although the gene fusions PAX3::FOXO1 and PAX7:: ... Full text Link to item Cite

Abstract A022-PR005: CDK8 Inhibition Releases the Muscle Differentiation Block in Fusion-Driven Alveolar Rhabdomyosarcoma

Conference Cancer Research · September 25, 2025 AbstractFunctional and chemical genomic approaches, such as the Broad Institute’s Cancer Dependency Map and PRISM (Profiling Relative Inhibition S ... Full text Cite

Prioritization of novel agents for further investigation in pediatric non-rhabdomyosarcoma soft tissue sarcomas: A report from the Children's Oncology Group.

Journal Article Eur J Cancer · August 26, 2025 Non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) is a group of over 70 tumors that occur across the age range and account for approximately 4 % of childhood cancers. Patients with metastatic or relapsed NRSTS have a dismal prognosis. The histologic, molecu ... Full text Link to item Cite
View All Publications

Recent Grants


Identification and targeting of essential regions of driver fusion oncoproteins in rhabdomyosarcoma

ResearchPrincipal Investigator · Awarded by V Foundation for Cancer Research · 2025 - 2030

Pharmacological Sciences Training Program

Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 2025 - 2030

Unified Program for Therapeutics in Children

Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 2025 - 2030

View All Grants

Education, Training & Certifications


Duke University · 1995 M.D.
Duke University · 1993 Ph.D.